Cancer's trajectory, as viewed by targets at AACR, ASCO and ASH
What new targets presented at 2019's AACR, ASCO and ASH meetings say about the future of cancer R&D
Beyond the headliner presentations at 2019’s three major cancer conferences were over a hundred posters and presentations showcasing new or emerging targets. A look at the identity of those targets reveals the growing diversity of approaches researchers are taking to manipulate the tumor microenvironment.
Between them, the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) meetings showcased 73 new therapeutic targets, defined as those with no active company programs against them and no entry in BioCentury’s BCIQ database, and 70 emerging targets, those with a marked increase in mentions at 2019’s conferences after appearing in two or fewer abstracts the previous year...